- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01522196
A Study of Varespladib Infusion in Subjects With Sickle Cell Disease. (IMPACTS-2)
January 30, 2014 updated by: Anthera Pharmaceuticals
A Randomized, Double-blind, Placebo-Controlled Study With Varespladib Infusion (A-001) in Subjects With Sickle Cell Disease and Vaso-Occlusive Crisis for the Prevention of Acute Chest Syndrome At-Risk Subjects.
The purpose of this study is to determine the effectiveness of A 001 infusion in preventing acute chest syndrome in sickle cell disease (SCD) subjects with vaso-occlusive crisis, fever, and elevated serum C-reactive protein (CRP).
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
2
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Investigator Site 101
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
5 years and older (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Genotypes Hb SS, Hb SC, sickle β°-thalassemia, sickle β+ -thalassemia
- Pain consistent with vaso-occlusive crisis (clinical judgment) and not attributable to other causes
- Serum CRP ≥5.0 mg/L at time of screening
- Fever defined as oral temperature ≥38.0°C at time of screening
- Age ≥5 years
Exclusion Criteria:
- New or suspected new pulmonary infiltrate diagnosed by chest radiography
- Females who are nursing, pregnant or intend to become pregnant
- Renal dysfunction defined as a creatinine level >1.2 mg/dL for subjects aged 18 or less or a creatinine level >1.5 mg/dL for subjects over the age of 18
- Hepatic dysfunction (alanine aminotransferase [ALT] or aspartate aminotransferase [AST] >3 × upper limit of normal)
- Acute neurologic dysfunction
- Any medical condition for which transfusion may be needed imminently, and/or hemoglobin <5 g/dL
- Red blood cell transfusion within 30 days prior to screening
- Parenteral or oral corticosteroid therapy (inhaled steroids acceptable) within 7 days prior to screening
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Varespladib
48 hour continuous infusion delivered intravenously (IV)
|
48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.
|
Placebo Comparator: Placebo
48 hour continuous infusion delivered intravenously (IV)
|
48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Efficacy of A 001 infusion in preventing acute chest syndrome in sickle cell disease (SCD) subjects with the combination of vaso-occlusive crisis, fever, and elevated serum C-reactive protein (CRP).
Time Frame: Various time points up to Day 30
|
Various time points up to Day 30
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety and tolerability of A 001 therapy when administered as a 48-hour continuous infusion to SCD subjects at-risk for acute chest syndrome.
Time Frame: Various time points up to Day 30
|
Various time points up to Day 30
|
Impact of A-001 treatment on sPLA2 levels and CRP.
Time Frame: Various time points up to Day 30
|
Various time points up to Day 30
|
Impact of A-001 treatment on the signs and symptoms of vaso-occlusive crisis.
Time Frame: Various time points up to Day 30
|
Various time points up to Day 30
|
Impact of A-001 treatment on opioid use for pain in the treatment of vaso-occlusive crisis.
Time Frame: Various time points up to Day 30
|
Various time points up to Day 30
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2012
Primary Completion (Actual)
March 1, 2012
Study Completion (Actual)
March 1, 2012
Study Registration Dates
First Submitted
January 18, 2012
First Submitted That Met QC Criteria
January 27, 2012
First Posted (Estimate)
January 31, 2012
Study Record Updates
Last Update Posted (Estimate)
March 4, 2014
Last Update Submitted That Met QC Criteria
January 30, 2014
Last Verified
January 1, 2014
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- AN-SCD1122
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sickle Cell Disease
-
Klein Buendel, Inc.National Institute on Minority Health and Health Disparities (NIMHD); Hilton...CompletedSickle Cell Disease | Sickle Cell Anemia in Children | Sickle Cell Thalassemia | Sickle Cell SC DiseaseUnited States
-
Nova Laboratories LimitedCompletedSickle Cell Disease | Sickle Cell Hemoglobin C | Sickle Cell-beta-thalassemia | Sickle-Cell; Hemoglobin Disease, ThalassemiaUnited Kingdom, Jamaica
-
SangartCompletedSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseUnited Kingdom, France, Jamaica, Lebanon
-
SangartWithdrawnSickle Cell Disease | Anemia, Sickle Cell | Sickle Cell Anemia | Hemoglobin SC Disease | Sickle Cell Disorders | Sickle Cell Hemoglobin C DiseaseFrance, United Kingdom, Netherlands, Turkey, Bahrain, Belgium, Brazil, Lebanon, Qatar
-
University of British ColumbiaCompletedSickle Cell Disease | Beta-Thalassemia | Sickle Cell Trait | Sickle Cell-Beta Thalassemia | Sickle Cell-SS DiseaseCanada, Nepal
-
Sidney Kimmel Cancer Center at Thomas Jefferson...National Heart, Lung, and Blood Institute (NHLBI)TerminatedSickle Cell Anemia | Sickle Cell-hemoglobin C Disease | Sickle Cell-β0-thalassemiaUnited States
-
University of RegensburgRecruitingSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | HbS Disease | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SGermany, Austria
-
Centre Hospitalier Intercommunal CreteilRecruitingSickle-Cell Disease Nos With CrisisFrance
-
HemaQuest Pharmaceuticals Inc.TerminatedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Egypt, Canada, Jamaica
-
HemaQuest Pharmaceuticals Inc.CompletedSickle Cell Disease | Sickle Cell Anemia | Sickle Cell Disorders | Hemoglobin S Disease | Sickling Disorder Due to Hemoglobin SUnited States, Lebanon, Canada, Egypt, Jamaica
Clinical Trials on Varespladib
-
Ophirex, Inc.RecruitingSnakebite | Envenoming, SnakeUnited States
-
Anthera PharmaceuticalsTerminatedRenal ImpairmentUnited States
-
Anthera PharmaceuticalsCompletedHealthy VolunteersUnited States
-
University Health Network, TorontoAnthera PharmaceuticalsCompletedCoronary Artery DiseaseCanada
-
Ophirex, Inc.Premier Research Group plcTerminatedCoronavirus Disease 2019 | Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2United States
-
Ophirex, Inc.Premier Research Group plcCompletedSnakebites | Envenoming | Envenoming, Snake | Envenomation, SnakeUnited States, India
-
Anthera PharmaceuticalsCompletedAcute Coronary SyndromeRussian Federation, Georgia, Ukraine
-
Anthera PharmaceuticalsTerminatedAcute Coronary SyndromeUnited States, Australia, Canada, Czech Republic, Georgia, Germany, Hungary, India, Italy, Korea, Republic of, Lebanon, Netherlands, New Zealand, Poland, Russian Federation, Spain, Ukraine
-
HK inno.N CorporationRecruiting
-
Regeneron PharmaceuticalsAvailable